PDUFA VI: Biosimilar Meetings Could Be Model For Earlier User Fee Payments
This article was originally published in The Pink Sheet Daily
Staggering the payment of fees during product development rather than paying all on application submission could enhance FDA's ability to hold timely meetings with sponsors, Avalere Senior VP Woollett says.
You may also be interested in...
Does PDUFA Need A Haircut? FDA Ponders Trimming Its Responsibilities
Acting Commissioner Ostroff wonders if all aspects of user fee program are delivering maximum added value.
Biosimilar User Fee Agreement Includes “Financial Hold” On Development Programs For Failure To Pay
Biosimilar INDs could be placed on “financial hold” if sponsors fail to timely pay product development fees under FDA’s inaugural biosimilar user fee deal with industry.
At Tofersen Panel Review, US FDA Shined A Light On Internal Differences Of Opinion
Agency’s presentations on Biogen/Ionis’ ALS drug included differing viewpoints from the statistical and clinical pharmacology teams; the transparency and emphasis on a multidisciplinary review approach may reflect lessons learned from missteps at the Aduhelm panel review in 2020.